Home LiteratureArticle Details
PMID: 18713817 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

The Journal of clinical endocrinology and metabolism ·Vol. 93 ·No. 11 ·2008-11-00 ·Pages 4331-41

Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR

Abstract

Cell lines derived from human cancers provide critical tools to study disease mechanisms and develop novel therapies. Recent reports indicate that up to 36% of cell lines are cross- contaminated. We evaluated 40 reported thyroid cancer-derived cell lines using short tandem repeat and single nucleotide polymorphism array analysis. Only 23 of 40 cell lines tested have unique genetic profiles. The following groups of cell lines are likely derivatives of the same cell line: BHP5-16, BHP17-10, BHP14-9, and NPA87; BHP2-7, BHP10-3, BHP7-13, and TPC1; KAT5, KAT10, KAT4, KAT7, KAT50, KAK1, ARO81-1, and MRO87-1; and K1 and K2. The unique cell lines include BCPAP, KTC1, TT2609-C02, FTC133, ML1, WRO82-1, 8505C, SW1736, Cal-62, T235, T238, Uhth-104, ACT-1, HTh74, KAT18, TTA1, FRO81-2, HTh7, C643, BHT101, and KTC-2. The misidentified cell lines included the DRO90-1, which matched the melanoma-derived cell line, A-375. The ARO81-1 and its derivatives matched the HT-29 colon cancer cell line, and the NPA87 and its derivatives matched the M14/MDA-MB-435S melanoma cell line. TTF-1 and Pax-8 mRNA levels were determined in the unique cell lines. Many of these human cell lines have been widely used in the thyroid cancer field for the past 20 yr and are not only redundant, but not of thyroid origin. These results emphasize the importance of cell line integrity, and provide the short tandem repeat profiles for a panel of thyroid cancer cell lines that can be used as a reference for comparison of cell lines from other laboratories.

MeSH Terms
Adenocarcinoma, Follicular/genetics Cell Culture Techniques/standards Cell Line, Tumor Colonic Neoplasms/genetics DNA, Neoplasm/genetics Female Gene Expression Profiling Humans Male Melanoma/genetics Mutation Neoplasm Proteins/genetics Polymorphism, Single Nucleotide RNA, Messenger/genetics Reproducibility of Results Thyroid Neoplasms/classification,genetics
Chemicals
DNA, Neoplasm Neoplasm Proteins RNA, Messenger
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Schweppe Rebecca E
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and University of Colorado Cancer Center, Denver, Aurora, Colorado 80045, USA. Rebecca.Schweppe@ucdenver.edu
Klopper Joshua P
Korch Christopher
Pugazhenthi Umarani
Benezra Miriam
Knauf Jeffrey A
Fagin James A
Marlow Laura A
Copland John A
Smallridge Robert C
Haugen Bryan R
References (77)
77 references, click to expand
  1. Establishment and biological characterization of an in vitro human cytomegalovirus latency model.
    Virology. 1987 Nov;161(1):62-72 PMID: 2823470
  2. Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression.
    Cancer Lett. 1997 Feb 26;113(1-2):77-86 PMID: 9065805
  3. Characterization and radiosensitivity at high or low dose rate of four cell lines derived from human thyroid tumors.
    Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):163-9 PMID: 9054892
  4. Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor.
    J Clin Endocrinol Metab. 1997 Aug;82(8):2633-8 PMID: 9253346
  5. Divergent effects of cytokines on human leukocyte antigen-DR antigen expression of neoplastic and non-neoplastic human thyroid cells.
    Cancer. 1992 Apr 1;69(7):1799-807 PMID: 1551065
  6. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
    Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 PMID: 18077425
  7. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status.
    J Clin Endocrinol Metab. 1999 Jul;84(7):2449-57 PMID: 10404820
  8. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    J Clin Endocrinol Metab. 2007 Dec;92(12):4686-95 PMID: 17911174
  9. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells.
    Proc Soc Exp Biol Med. 1997 Mar;214(3):248-57 PMID: 9083258
  10. TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin.
    Cancer Res. 2001 Sep 1;61(17):6340-4 PMID: 11522622
  11. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
    J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 PMID: 14602780
  12. Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines.
    J Clin Endocrinol Metab. 1996 Jul;81(7):2607-12 PMID: 8675585
  13. Molecular characterization of human prostate carcinoma cell lines.
    Prostate. 2003 Nov 1;57(3):205-25 PMID: 14518029
  14. Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies.
    Surgery. 1990 Dec;108(6):1065-71 PMID: 1978945
  15. Widely used prostate carcinoma cell lines share common origins.
    Prostate. 2001 Apr;47(1):36-51 PMID: 11304728
  16. Cancer cell line identification by short tandem repeat profiling: power and limitations.
    FASEB J. 2005 Mar;19(3):434-6 PMID: 15637111
  17. Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50.
    Thyroid. 1998 Jan;8(1):63-9 PMID: 9492156
  18. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
    Int J Cancer. 2005 May 20;115(1):164-9 PMID: 15657897
  19. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Clin Cancer Res. 2007 Feb 15;13(4):1341-9 PMID: 17317846
  20. Growth suppression of thyroid cancer cells by adenylcyclase activator.
    Oncol Rep. 2007 Aug;18(2):441-5 PMID: 17611668
  21. Susceptibility of thyroid cancer cells to 7-hydroxystaurosporine-induced apoptosis correlates with Bcl-2 protein level.
    Thyroid. 2001 Aug;11(8):725-31 PMID: 11525264
  22. Formation and growth of multicellular spheroids of human origin.
    Int J Cancer. 1983 May 15;31(5):523-33 PMID: 6852971
  23. Humoral immune response to intralymphatic immunotherapy for disseminated melanoma: correlation with clinical response.
    Surgery. 1982 Aug;92(2):362-7 PMID: 7101129
  24. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29.
    Cancer Genet Cytogenet. 1987 Jul;27(1):125-34 PMID: 3472642
  25. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.
    Cancer Res. 2004 Mar 1;64(5):1664-8 PMID: 14996725
  26. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors.
    Endocrinology. 2005 Sep;146(9):3967-74 PMID: 15919754
  27. Clonally related but phenotypically divergent human cancer cell lines derived from a single follicular thyroid cancer recurrence (TT2609).
    Thyroid. 2001 Oct;11(10):909-17 PMID: 11716037
  28. Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells.
    Jpn J Cancer Res. 2002 Dec;93(12):1358-65 PMID: 12495476
  29. Mutated E-cadherin: genomic and functional characterization in thyroid cells from the KAT family.
    Thyroid. 2004 Nov;14(11):902-9 PMID: 15671768
  30. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
    Cancer Res. 2003 Apr 1;63(7):1454-7 PMID: 12670889
  31. Overexpression of thyroid hormone receptor beta1 is associated with thyrotropin receptor gene expression and proliferation in a human thyroid carcinoma cell line.
    J Endocrinol. 2000 May;165(2):379-89 PMID: 10810302
  32. Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101).
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1993;63(4):263-9 PMID: 8099464
  33. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Cancer Res. 2003 Aug 1;63(15):4561-7 PMID: 12907632
  34. Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.
    Cancer Res. 2007 Sep 1;67(17):8113-20 PMID: 17804723
  35. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?
    Biotechniques. 2007 Nov;43(5):575, 577-8, 581-2 passim PMID: 18072586
  36. Widespread intraspecies cross-contamination of human tumor cell lines arising at source.
    Int J Cancer. 1999 Nov 12;83(4):555-63 PMID: 10508494
  37. Decreased growth rate and tumour formation of human anaplastic thyroid carcinoma cells transfected with a human thyrotropin receptor cDNA in NMRI nude mice treated with propylthiouracil.
    Mol Cell Endocrinol. 1996 Aug 9;121(2):143-51 PMID: 8892315
  38. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.
    J Natl Cancer Inst. 1973 Nov;51(5):1417-23 PMID: 4357758
  39. Mutations of the BRAF gene in human cancer.
    Nature. 2002 Jun 27;417(6892):949-54 PMID: 12068308
  40. Cell biology. Cases of mistaken identity.
    Science. 2007 Feb 16;315(5814):928-31 PMID: 17303729
  41. Growth regulation of normal thyroids and thyroid tumors in man.
    Recent Results Cancer Res. 1990;118:48-63 PMID: 2173080
  42. Coexpression of functionally active receptors for thyrotropin and platelet-derived growth factor in human thyroid carcinoma cells.
    Endocrinology. 1991 Oct;129(4):2187-93 PMID: 1655394
  43. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Mol Cancer Res. 2007 Feb;5(2):195-201 PMID: 17314276
  44. Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin.
    Endocrinology. 1989 Oct;125(4):1783-8 PMID: 2551628
  45. Establishment and characterization of a human papillary thyroid carcinoma cell line with oxyphilic differentiation (ONCO-DG 1).
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;62(2):97-104 PMID: 1381131
  46. Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2.
    Thyroid. 2003 Mar;13(3):249-58 PMID: 12729473
  47. Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties.
    Clin Exp Metastasis. 2004;21(6):543-52 PMID: 15679052
  48. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.
    J Clin Invest. 2005 Apr;115(4):1068-81 PMID: 15761501
  49. Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers.
    Cancer. 1994 Apr 15;73(8):2206-12 PMID: 8156527
  50. [Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland].
    Bull Cancer. 1991 Nov;78(11):1053-62 PMID: 1369551
  51. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.
    J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 PMID: 12970315
  52. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines.
    J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62 PMID: 9177396
  53. Establishment and characterization of the follicular thyroid carcinoma cell line ML-1.
    J Mol Med (Berl). 2000;78(2):102-10 PMID: 10794546
  54. Persistent use of "false" cell lines.
    Int J Cancer. 2008 Jan 1;122(1):1-4 PMID: 17960586
  55. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
    J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201 PMID: 18381570
  56. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo.
    Endocrinology. 1997 Nov;138(11):4577-83 PMID: 9348181
  57. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.
    J Clin Endocrinol Metab. 2004 Jan;89(1):272-80 PMID: 14715861
  58. Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium.
    Cancer Res. 1976 Apr;36(4):1503-9 PMID: 1260767
  59. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro.
    J Clin Endocrinol Metab. 1994 May;78(5):1097-102 PMID: 7909817
  60. Short tandem repeat profiling provides an international reference standard for human cell lines.
    Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 PMID: 11416159
  61. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines.
    Arch Pathol Lab Med. 2007 Jan;131(1):65-73 PMID: 17227125
  62. MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research.
    Breast Cancer Res Treat. 2007 Jul;104(1):13-9 PMID: 17004106
  63. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
    Oncogene. 1997 Feb 13;14(6):729-40 PMID: 9038381
  64. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
    Oncogene. 2005 Sep 15;24(41):6292-302 PMID: 16007203
  65. Quantitative and qualitative differences in growth, invasion and lung colonization of an anaplastic and a papillary human thyroid cancer cell line in vitro and in vivo.
    Clin Exp Metastasis. 1996 Oct;14(5):440-50 PMID: 8871538
  66. Cell biology. When 60 lines don't add up.
    Science. 2007 Feb 16;315(5814):929 PMID: 17303730
  67. Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
    Thyroid. 2007 Aug;17(8):707-15 PMID: 17725429
  68. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Cancer Res. 2002 Nov 15;62(22):6451-5 PMID: 12438234
  69. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1).
    Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;57(3):167-74 PMID: 2570483
  70. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.
    J Clin Endocrinol Metab. 2000 Aug;85(8):2889-96 PMID: 10946899
  71. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.
    J Clin Endocrinol Metab. 2005 Sep;90(9):5270-8 PMID: 15998773
  72. A highly discriminating octoplex short tandem repeat polymerase chain reaction system suitable for human individual identification.
    Electrophoresis. 1995 Mar;16(3):334-7 PMID: 7607165
  73. Evidence for diminished functional expression of intestinal transporters in Caco-2 cell monolayers at high passages.
    Pharm Res. 1997 Jun;14(6):757-62 PMID: 9210193
  74. In vitro irradiation is able to cause RET oncogene rearrangement.
    Cancer Res. 1993 Jul 1;53(13):2940-3 PMID: 8319199
  75. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines.
    Br J Cancer. 2007 Apr 23;96(8):1237-45 PMID: 17406368
  76. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
    Thyroid. 2007 Apr;17(4):289-301 PMID: 17465858
  77. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    J Clin Endocrinol Metab. 2007 Dec;92(12):4712-8 PMID: 17878251
Article Info
Journal
The Journal of clinical endocrinology and metabolism
Abbr.
J Clin Endocrinol Metab
ISSN
0021-972X
DOI
10.1210/jc.2008-1102
Email
rebecca.schweppe@ucdenver.edu
Published
2008-11-00
Epub
2008-00-19
Pages
4331-41
Language
English
Region
United States
NLM ID
0375362
PMCID
PMC2582569
Subset
IM
Grants
NCI NIH HHS · R01 CA072597 · United States
NCI NIH HHS · CA100560 · United States
NCI NIH HHS · R01 CA050706 · United States
NCI NIH HHS · CA72597 · United States
NCI NIH HHS · P30 CA046934 · United States
NCI NIH HHS · CA50706 · United States
NCI NIH HHS · P30CA15083 · United States
NCI NIH HHS · R01 CA100560 · United States
NCI NIH HHS · P30 CA015083 · United States
Corrections
CommentIn
PMID: 18987282
CommentIn
PMID: 23472229
External Links
PubMed source DOI: 10.1210/jc.2008-1102 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2